EXAS Key Stats
- 6 Ways You Can Profit From Molecular Diagnostics May 22
- Exact Sciences Corporation Presents at UBS Global Healthcare Conference, May-21-... May 21
- A Game-Changing Cancer Screen For Exact Sciences May 21
- EXACT Sciences (EXAS) Shares Cross Above 200 DMA May 14
- EXACT SCIENCES CORP Financials May 10
- Why Exact Sciences Is Poised to Underperform May 3
- Exact Sciences to Participate in May Investor Conferences Business Wire May 3
- EXACT SCIENCES CORP Files SEC form 8-K, Change in Directors or Principal Officer... May 3
- EXACT SCIENCES CORP Files SEC form 10-Q, Quarterly Report May 3
- Exact Sciences Management Discusses Q1 2013 Results - Earnings Call Transcript Seeking Alpha May 1
EXAS Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Exact Sciences Corporation is up 5.01% over the last year vs S&P 500 Total Return up 27.77%, Array BioPharma up 60.27%, and Cadence Pharmaceuticals up 146.8%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Pro Ratings for EXAS
Pro Report PDF for EXAS
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download EXAS Pro Report PDF
Pro Strategies Featuring EXAS
Did Exact Sciences Corporation make it into our Pro Portfolio Strategies?